4237919 said its normalized net income for the fiscal first quarter ended June 30 amounted to ¥27.53 per share, a decrease of 13.6% from ¥31.85 per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥2.25 billion, a decrease of 13.8% from ¥2.61 billion in the prior-year period.
The normalized profit margin fell to 8.3% from 9.6% in the year-earlier period.
Total revenue totaled ¥27.17 billion, compared with ¥27.21 billion in the year-earlier period, and total operating expenses increased on an annual basis to ¥23.84 billion from ¥23.27 billion.
Reported net income fell 18.5% on an annual basis to ¥2.42 billion, or ¥29.57 per share, from ¥2.96 billion, or ¥36.19 per share.
s of Aug. 6, US$1 was equivalent to ¥102.36.Kobayashi Pharmaceutical Co. Ltd.
4237919 said its normalized net income for the fiscal first quarter ended June 30 amounted to ¥27.53 per share, a decrease of 13.6% from ¥31.85 per share in the year-earlier period.
